Exelixis
EXEL
#2109
Rank
S$9.81 B
Marketcap
$34.41
Share price
-1.53%
Change (1 day)
17.04%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of June 2024 : S$2.76 B

According to Exelixis's latest financial reports the company has S$2.76 B in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$S$2.98 B-10.37%
2022-12-31$S$3.33 B11.9%
2021-12-31$S$2.98 B20%
2020-12-31$S$2.48 B9.58%
2019-12-31$S$2.26 B29.27%
2018-12-31$S$1.75 B360.16%
2017-12-31$S$0.38 B194.84%
2016-12-31$S$0.12 B-164.84%
2015-12-31$-S$0.2 B31.4%
2014-12-31$-S$0.16 B-280.76%
2013-12-31$S$83.93 M-76.86%
2012-12-31$S$0.36 B209.05%
2011-12-31$S$0.11 B-139.89%
2010-12-31$-S$0.3 B27.89%
2009-12-31$-S$0.24 B184.39%
2008-12-31$-S$80.91 M-165.43%
2007-12-31$S$0.12 B-11.01%
2006-12-31$S$0.13 B45.65%
2005-12-31$S$95.39 M27.68%
2004-12-31$S$74.71 M-72.81%
2003-12-31$S$0.27 B-9.96%
2002-12-31$S$0.30 B-30.49%
2001-12-31$S$0.43 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
S$22.69 B 721.92%๐Ÿ‡ฌ๐Ÿ‡ง UK
S$101.92 B 3,591.58%๐Ÿ‡ซ๐Ÿ‡ท France
S$56.85 B 1,959.13%๐Ÿ‡บ๐Ÿ‡ธ USA
S$22.23 B 705.24%๐Ÿ‡บ๐Ÿ‡ธ USA
S$7.71 B 179.52%๐Ÿ‡บ๐Ÿ‡ธ USA
S$93.18 B 3,274.86%๐Ÿ‡บ๐Ÿ‡ธ USA
S$114.59 B 4,050.29%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$0.91 M-100.03%๐Ÿ‡บ๐Ÿ‡ธ USA
S$37.57 M-98.64%๐Ÿ‡บ๐Ÿ‡ธ USA